Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Immune reactivity after adenoviral-mediated aquaporin-1 cDNA transfer to human parotid glands.

Alevizos I, Zheng C, Cotrim AP, Goldsmith CM, McCullagh L, Berkowitz T, Strobl SL, Malyguine A, Kopp WC, Chiorini JA, Nikolov NP, Neely M, Illei GG, Baum BJ.

Oral Dis. 2017 Apr;23(3):337-346. doi: 10.1111/odi.12614. Epub 2017 Feb 8.

2.

Characterization of effect of repeated freeze and thaw cycles on stability of genomic DNA using pulsed field gel electrophoresis.

Shao W, Khin S, Kopp WC.

Biopreserv Biobank. 2012 Feb;10(1):4-11. doi: 10.1089/bio.2011.0016.

PMID:
24849748
3.

Peripheral blood immunologic phenotype of population-based breast cancer cases and matched controls.

Goedert JJ, Pfeiffer R, Zhu M, Yang XR, Garcia-Closas M, Lissowska J, Kopp WC.

Eur J Clin Invest. 2012 May;42(5):572-4. doi: 10.1111/j.1365-2362.2011.02610.x. Epub 2011 Nov 11. No abstract available.

4.

IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood.

Sneller MC, Kopp WC, Engelke KJ, Yovandich JL, Creekmore SP, Waldmann TA, Lane HC.

Blood. 2011 Dec 22;118(26):6845-8. doi: 10.1182/blood-2011-09-377804. Epub 2011 Nov 8.

5.

Lymphocyte subsets in hemophilic patients with hepatitis C virus infection with or without human immunodeficiency virus co-infection: a nested cross-sectional study.

Zhang M, O'brien TR, Kopp WC, Goedert JJ; for the Multicenter Hemophilia Cohort Study.

BMC Blood Disord. 2005 Jan 18;5(1):2.

6.

Whole blood cryopreservation in epidemiological studies.

Hayes RB, Smith CO, Huang WY, Read Y, Kopp WC.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1496-8.

7.

Correlation of human CD56+ cell cytotoxicity and IFN-gamma production.

Derby EG, Reddy V, Nelson EL, Kopp WC, Baseler MW, Dawson JR, Malyguine AM.

Cytokine. 2001 Jan 21;13(2):85-90.

PMID:
11145847
8.

Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.

Arun B, Curti BD, Longo DL, Stevens D, Alvord WG, Gause BL, Watson T, Kopp WC, Janik JE.

Cancer J Sci Am. 2000 Jan-Feb;6(1):21-4.

PMID:
10696734
9.

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH.

J Clin Oncol. 2000 Feb;18(4):927-41.

PMID:
10673536
10.

Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.

Janik JE, Miller LL, Kopp WC, Taub DD, Dawson H, Stevens D, Kostboth P, Curti BD, Conlon KC, Dunn BK, Donegan SE, Ullrich R, Alvord WG, Gause BL, Longo DL.

Clin Immunol. 1999 Dec;93(3):209-21.

PMID:
10600331
11.
12.

Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.

Miller LL, Korn EL, Stevens DS, Janik JE, Gause BL, Kopp WC, Holmlund JT, Curti BD, Sznol M, Smith JW 2nd, Urba WJ, Donegan SE, Watson TM, Longo DL.

Blood. 1999 May 15;93(10):3250-8.

PMID:
10233876
13.

Conditioned immune response to interferon-gamma in humans.

Longo DL, Duffey PL, Kopp WC, Heyes MP, Alvord WG, Sharfman WH, Schmidt PJ, Rubinow DR, Rosenstein DL.

Clin Immunol. 1999 Feb;90(2):173-81.

PMID:
10080828
14.

Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.

Curti BD, Ochoa AC, Powers GC, Kopp WC, Alvord WG, Janik JE, Gause BL, Dunn B, Kopreski MS, Fenton R, Zea A, Dansky-Ullmann C, Strobl S, Harvey L, Nelson E, Sznol M, Longo DL.

J Clin Oncol. 1998 Aug;16(8):2752-60.

PMID:
9704728
15.

Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin.

Yoe J, Gause BL, Curti BD, Longo DL, Bagg A, Kopp WC, Janik JE.

Am J Hematol. 1998 Mar;57(3):253-7.

16.

Interleukin 1 alpha increases serum leptin concentrations in humans.

Janik JE, Curti BD, Considine RV, Rager HC, Powers GC, Alvord WG, Smith JW 2nd, Gause BL, Kopp WC.

J Clin Endocrinol Metab. 1997 Sep;82(9):3084-6.

PMID:
9284748
17.

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.

Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW 2nd, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL.

J Clin Oncol. 1996 Aug;14(8):2234-41.

PMID:
8708712
18.

Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.

Curti BD, Ochoa AC, Urba WJ, Alvord WG, Kopp WC, Powers G, Hawk C, Creekmore SP, Gause BL, Janik JE, Holmlund JT, Kremers P, Fenton RG, Miller L, Sznol M, Smith JW 2nd, Sharfman WH, Longo DL.

J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):296-308.

PMID:
8877723
19.

Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer.

Kopp WC, Urba WJ, Rager HC, Alvord WG, Oppenheim JJ, Smith JW 2nd, Longo DL.

Clin Cancer Res. 1996 Mar;2(3):501-6.

20.

Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.

Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW 2nd.

J Natl Cancer Inst. 1996 Jan 3;88(1):44-9.

PMID:
8847725
21.

Cytokines and immunological monitoring.

Kopp WC, Holmlund JT.

Cancer Chemother Biol Response Modif. 1996;16:189-238. Review. No abstract available.

PMID:
8639383
22.

Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.

Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, et al.

Blood. 1995 Jun 15;85(12):3457-65.

PMID:
7780133
23.

A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2.

Holmund JT, Kopp WC, Wiltrout RH, Longo DL, Urba WJ, Janik JE, Sznol M, Conlon KC, Fenton RG, Hornung R, et al.

J Natl Cancer Inst. 1995 Jan 18;87(2):134-6. No abstract available.

PMID:
7707385
24.

Immunological monitoring and clinical trials of biological response modifiers.

Kopp WC, Holmlund JT, Urba WJ.

Cancer Chemother Biol Response Modif. 1994;15:226-86. Review. No abstract available.

PMID:
7540029
25.

Levamisole-induced neopterin synthesis.

Janik J, Kopp WC, Smith JW 2nd, Longo DL, Alvord WG, Urba WJ.

Ann N Y Acad Sci. 1993 Jun 23;685:252-8. No abstract available.

PMID:
8363229
26.

Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.

Kopp WC, Smith JW 2nd, Ewel CH, Alvord WG, Main C, Guyre PM, Steis RG, Longo DL, Urba WJ.

J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):181-90.

PMID:
8471592
27.

Dose-related immunologic effects of levamisole in patients with cancer.

Janik J, Kopp WC, Smith JW 2nd, Longo DL, Alvord WG, Sharfman WH, Fenton RG, Sznol M, Steis RG, Creekmore SP, et al.

J Clin Oncol. 1993 Jan;11(1):125-35.

PMID:
8418223
28.

Immunological monitoring and clinical trials of biological response modifiers.

Baseler MW, Kopp WC, Urba WJ.

Cancer Chemother Biol Response Modif. 1993;14:249-83. Review. No abstract available.

PMID:
7508729
29.

Enhanced lymphokine production and lymphokine receptor expression in multiple antibody-stimulated human CD4+ peripheral blood lymphocytes.

Conlon KC, Ochoa AC, Kopp WC, Ortaldo JR, Urba WJ, Longo DL, Young HA.

J Immunol. 1992 Nov 15;149(10):3278-89.

PMID:
1358968
30.

Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells.

Loeffler CM, Smyth MJ, Longo DL, Kopp WC, Harvey LK, Tribble HR, Tase JE, Urba WJ, Leonard AS, Young HA, et al.

J Immunol. 1992 Aug 1;149(3):949-56.

PMID:
1353099
31.

Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen.

Stinson SF, Alley MC, Kopp WC, Fiebig HH, Mullendore LA, Pittman AF, Kenney S, Keller J, Boyd MR.

Anticancer Res. 1992 Jul-Aug;12(4):1035-53.

PMID:
1503399
32.

Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.

Ewel CH, Urba WJ, Kopp WC, Smith JW 2nd, Steis RG, Rossio JL, Longo DL, Jones MJ, Alvord WG, Pinsky CM, et al.

Cancer Res. 1992 Jun 1;52(11):3005-10.

33.

Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients.

Steis RG, Urba WJ, Kopp WC, Alvord WG, Smith JW 2nd, Longo DL.

J Natl Cancer Inst. 1991 Nov 20;83(22):1678-9. No abstract available.

PMID:
1684207
34.

The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa.

Urba WJ, Kopp WC, Clark JW, Smith JW 2nd, Steis RG, Huber C, Coggin D, Longo DL.

J Clin Oncol. 1991 Oct;9(10):1831-9.

PMID:
1919633
35.

Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells.

Hestdal K, Ruscetti FW, Ihle JN, Jacobsen SE, Dubois CM, Kopp WC, Longo DL, Keller JR.

J Immunol. 1991 Jul 1;147(1):22-8.

PMID:
1711076
36.

Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.

Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW 2nd, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC, et al.

Cancer Res. 1990 May 15;50(10):2979-86.

37.

Enhanced antibody response in the presence of partial adenosine deaminase inhibition.

Hoffman EA, Kopp WC, Moat AG.

Proc Soc Exp Biol Med. 1990 May;194(1):36-42.

PMID:
2139230
38.

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial.

Steis RG, VanderMolen LA, Longo DL, Clark JW, Smith JW 2nd, Kopp WC, Ruscetti FW, Creekmore SP, Elwood LJ, Hursey J, et al.

J Natl Cancer Inst. 1990 Apr 18;82(8):697-703.

PMID:
2138680
39.

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.

Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clark JW.

Cancer Res. 1990 Jan 1;50(1):185-92.

PMID:
2293554
40.

Alteration of the B cell surface phenotype, immune response to phosphocholine and the B cell repertoire in M167 mu plus kappa transgenic mice.

Kenny JJ, Finkelman F, Macchiarini F, Kopp WC, Storb U, Longo DL.

J Immunol. 1989 Jun 15;142(12):4466-74.

PMID:
2498429
41.
42.

Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.

Urba WJ, Baseler MW, Kopp WC, Steis RG, Clark JW, Smith JW 2nd, Coggin DL, Longo DL.

Blood. 1989 Jan;73(1):38-46.

PMID:
2783373
43.

Synthesis of fluorescent muramyl dipeptide congeners. 2.

Hiebert CK, Kopp WC, Richerson HB, Barfknecht CF.

J Med Chem. 1988 Oct;31(10):2022-4.

PMID:
3172138
44.

Alveolar macrophage immunosuppression is maintained in rabbit models of hypersensitivity pneumonitis.

Kopp WC, Suelzer MT, Richerson HB.

J Allergy Clin Immunol. 1988 Aug;82(2):204-12.

PMID:
2457042
45.

T cell localization in rabbit models of acute and chronic experimental hypersensitivity pneumonitis.

Upadrashta B, Croom J, Kopp WC, Withers J, Richerson HB.

J Allergy Clin Immunol. 1988 May;81(5 Pt 1):821-8.

PMID:
3259594
46.

Financial evaluation of HMOs and PPOs.

Goldman RL, Shoen CB, Kopp WC.

Health Mark Q. 1988;5(3-4):89-100. No abstract available.

PMID:
10292532
47.
48.

Retirement centers. Where housing meets healthcare.

Clunn BA, Kopp WC, Lasman GA.

Healthc Exec. 1987 Mar-Apr;2(2):44-8. No abstract available.

PMID:
10301532
49.

Effects of cyclosporine on pulmonary clearance of Staphylococcus aureus and Pseudomonas aeruginosa.

Nugent KM, Kopp WC.

J Infect Dis. 1986 Aug;154(2):352-5. No abstract available.

PMID:
3088134
50.

Cyclosporine immunomodulation in a rabbit model of chronic hypersensitivity pneumonitis.

Kopp WC, Dierks SE, Butler JE, Upadrashta BS, Richerson HB.

Am Rev Respir Dis. 1985 Nov;132(5):1027-33.

PMID:
4062034

Supplemental Content

Support Center